FY2026 EPS Estimates for Roche Decreased by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Stock analysts at Erste Group Bank cut their FY2026 EPS estimates for shares of Roche in a report released on Friday, June 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.18 per share for the year, down from their previous estimate of $3.23. The consensus estimate for Roche’s current full-year earnings is $3.29 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.42 EPS.

Several other equities research analysts have also weighed in on RHHBY. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price on the stock in a report on Friday, April 24th. Argus raised Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Finally, Wolfe Research reiterated an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $51.50.

Roche Price Performance

OTCMKTS RHHBY opened at $51.65 on Monday. Roche has a 1-year low of $37.51 and a 1-year high of $60.85. The stock’s 50 day moving average is $51.06 and its two-hundred day moving average is $52.46. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Hedge Funds Weigh In On Roche

Several institutional investors and hedge funds have recently modified their holdings of RHHBY. Curio Wealth LLC acquired a new position in shares of Roche in the third quarter valued at approximately $25,000. McIlrath & Eck LLC acquired a new stake in shares of Roche in the 1st quarter valued at approximately $39,000. Oakworth Capital Inc. lifted its stake in Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after acquiring an additional 285 shares during the last quarter. Atlas Capital Advisors Inc. acquired a new stake in Roche in the 4th quarter valued at about $192,000. Finally, Albert D Mason Inc. acquired a new stake in Roche in the 4th quarter valued at about $207,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.